<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827851</url>
  </required_header>
  <id_info>
    <org_study_id>RU-ССН-03-01-16</org_study_id>
    <nct_id>NCT02827851</nct_id>
  </id_info>
  <brief_title>Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy</brief_title>
  <official_title>Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orenburg Regional Clinical Blood Donor Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stromal vascular fraction of cells (SVF) will be extracted from lipoaspirate by enzymatic&#xD;
      digestion. SVF will be administered in a single dose intraarticularly 4 weeks after&#xD;
      arthroscopic debridement. All patients will receive cell therapy.This is a single arm study&#xD;
      with no control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergone arthroscopic debridement for knee osteoarthritis will be subjected to&#xD;
      abdominal liposuction under local anaesthesia. Harvested adipose tissue will be processed&#xD;
      according to patent pending technology based on enzymatic digestion, washing and&#xD;
      concentration of cell pellet in 5 ml of Hartmann's solution. Isolated SVF will be&#xD;
      administered in a single dose into anterior part of knee joint cavity 28 days after&#xD;
      arthroscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAEs monitoring</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Types, probability and severity of treatment emergent serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARs monitoring</measure>
    <time_frame>4 weeks after treatment</time_frame>
    <description>Types, probability and severity of treatment emergent serious adverse reactions (SARs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life monitoring-1</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Quality of life estimated by validated questionnaire - the Short Form (36) Health Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life monitoring-2</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Quality of life estimated by validated questionnaire - Knee Injury and Osteoarthritis Outcome Score (KOOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain intensity monitoring</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Knee pain intensity assessed by Visual Analog Pain Scale (no pain=0; maximum pain=100 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-1</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by ultrasonography (effusion, synovial thickening or hypertrophy, cartilage parameters, vascularity, Baker's cysts, osteophytes, tendon and ligament abnormalities, meniscal changes, bursitis, erosions and panniculitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-2</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by X-ray (joint space width, bone contour, presence of osteophytes and sclerosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee joint structure-3</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee joint structure assessed by MRI (articular cartilage, osteophytes, bone marrow abnormality, meniscal integrity, synovial effusion/tissue, anterior and posterior cruciate ligaments, and medial and lateral collateral ligaments)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in knee function</measure>
    <time_frame>Follow up to completion (up to 24 weeks after treatment)</time_frame>
    <description>Changes in knee function assessed by validated questionnaire: Knee Society Score (KSS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>SVF injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liposuction</intervention_name>
    <arm_group_label>SVF injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SVF isolation</intervention_name>
    <description>SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.</description>
    <arm_group_label>SVF injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intraarticular administration of autologous SVF</intervention_name>
    <arm_group_label>SVF injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pain in the knee joint during more than a half day assessed by Visual Analog Pain&#xD;
             Scale (score more than 40 mm)&#xD;
&#xD;
          -  At least three of the following 6 criteria: 50 years of age or older, stiffness&#xD;
             lasting less than 30 minutes, crepitus, bony tenderness, bony enlargement, no warmth&#xD;
             to the touch&#xD;
&#xD;
          -  Patient is able to walk without assistance&#xD;
&#xD;
          -  Patient is familiar with Participant information sheet&#xD;
&#xD;
          -  Patient signed informed consent form&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Medical history of endoprosthetic knee replacement&#xD;
&#xD;
          -  Medical history of lower extremity osteotomy&#xD;
&#xD;
          -  Medical history of knee surgery (including arthroscopy) during preceding 1 year prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Medical history of intraarticular injections during preceding 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Secondary osteoarthritis of the knee joint: posttraumatic osteoarthritis (developed&#xD;
             after clinically significant injury), intra-articular fractures, clinically&#xD;
             significant varus or valgus deformities of lower limbs, septic arthritis, joint's&#xD;
             inflammatory disorders, gout, advanced chondrocalcinosis, Paget's disease, ochronosis,&#xD;
             acromegaly, hemochromatosis, Wilson's disease, primary synovial osteochondromatosis,&#xD;
             osteonecrosis, hemophilia&#xD;
&#xD;
          -  Patients prescribed for immunosuppressive treatment&#xD;
&#xD;
          -  Medical history of systemic autoimmune and inflammatory diseases&#xD;
&#xD;
          -  Significant weight loss (&gt; 10% of body weight in the previous year) of unknown&#xD;
             etiology&#xD;
&#xD;
          -  Medical history of venous thromboembolism or estimated high risk of venous&#xD;
             thromboembolism&#xD;
&#xD;
          -  Patients prescribed for systemic corticosteroids or other medications treatment with&#xD;
             proven impact on bone or cartilage tissue metabolism&#xD;
&#xD;
          -  Clinically significant abnormalities in results of laboratory tests&#xD;
&#xD;
          -  Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and&#xD;
             alcohol abuse etc.)&#xD;
&#xD;
          -  Participation in other clinical trials (or administration of investigational drugs)&#xD;
             during 3 months prior inclusion&#xD;
&#xD;
          -  Patients with malignant tumors including postoperative period, patients receiving&#xD;
             chemotherapy and/or radiotherapy.&#xD;
&#xD;
          -  Patient's activated partial thromboplastin time exceeds normal levels more than 1,8&#xD;
             times&#xD;
&#xD;
          -  Patients prescribed for anticoagulants treatment or patient received anticoagulants at&#xD;
             least one hour prior liposuction&#xD;
&#xD;
          -  Medical history of heterotopic ossifications&#xD;
&#xD;
          -  Patients prescribed for glycoprotein inhibitors treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's refusal from the further participation in trial&#xD;
&#xD;
          -  Patient's refusal from compliance with the requirements of contraception during the&#xD;
             participation in research&#xD;
&#xD;
          -  Chronic kidney disease IV- V stages (creatinine clearance &lt; 30 mL/min estimated by&#xD;
             Cockcroft-Gault formula)&#xD;
&#xD;
          -  Confirmed syphilis, HIV, hepatitis B or C infections&#xD;
&#xD;
        Dropout Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya I Eremin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Central Clinical Hospital with Outpatient Health Center&quot; of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinat G Gilmutdinov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orenburg Regional Clinical Donor Blood Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergey I Gilfanov, MD, PhD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution &quot;Central Clinical Hospital with Outpatient Health Center&quot; of the Business Administration for the President of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrey A Averyanov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orenburg Regional Clinical Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vadim A Kopylov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orenburg City Clinical Hospital #4</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal State Budgetary Institution &quot;Central Clinical Hospital with Outpatient Health Center&quot; of the Business Administration for the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg City Clinical Hospital #4</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Donor Blood Center</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orenburg Regional Clinical Hospital</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Damage of articular cartilage</keyword>
  <keyword>Cartilage degeneration</keyword>
  <keyword>Intraarticular injection</keyword>
  <keyword>SVF</keyword>
  <keyword>Stromal vascular fraction</keyword>
  <keyword>Adipose-derived regenerative cells (ADRC)</keyword>
  <keyword>Adipose tissue</keyword>
  <keyword>Stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

